C4 Therapeutics Ownership | Who Owns C4 Therapeutics?

Overview Forecast RevenueFinancials Chart

C4 Therapeutics Ownership Summary

C4 Therapeutics is owned by 30.31% institutional investors, 9.79% insiders, and 59.90% retail investors. Lynx1 capital management lp is the largest institutional shareholder, holding 10.23% of CCCC shares. Wasatch Ultra Growth is the top mutual fund, with 6.42% of its assets in C4 Therapeutics shares.

CCCC Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	C4 Therapeutics	30.31%	9.79%	59.90%
Sector	Healthcare Stocks	279.17%	10.51%	-189.68%
Industry	Biotech Stocks	63.95%	10.67%	25.38%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Lynx1 capital management lp	7.10M	10.23%	$11.36M
Soleus capital management	6.98M	10.06%	$11.17M
Orbimed advisors	6.83M	9.85%	$10.93M
Wasatch advisors lp	6.07M	8.72%	$21.86M
Blackrock funding, inc. /de	5.56M	7.98%	$20.01M
Blackrock	4.55M	6.61%	$21.03M
Vanguard group	3.35M	4.81%	$12.05M
Samlyn capital	3.02M	4.34%	$10.87M
Bank of america corp /de/	1.77M	2.57%	$8.17M
Adage capital partners gp	1.55M	2.23%	$5.58M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Lynx1 capital management lp	7.10M	4.07%	$11.36M
Silverarc capital management	1.22M	0.96%	$4.40M
Soleus capital management	6.98M	0.80%	$11.17M
Bain capital life sciences investors	1.11M	0.47%	$4.00M
Orbimed advisors	6.83M	0.26%	$10.93M
Tang capital management	900.00K	0.21%	$3.24M
Vienna powszechne towarzystwo emerytalne s.a. vienna insurance group	85.00K	0.18%	$306.00K
Samlyn capital	3.02M	0.16%	$10.87M
Wasatch advisors lp	6.07M	0.11%	$21.86M
Intrepid family office	40.00K	0.09%	$64.00K

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	4.55M	0.00%	3.65M
Samlyn capital	3.02M	0.16%	3.02M
Orbimed advisors	6.83M	0.26%	2.45M
Adage capital partners gp	1.55M	0.01%	1.03M
Blackrock funding, inc. /de	5.56M	0.00%	667.92K

Top Sellers

Holder	Shares	% Assets	Change
Ra capital management	-	-	-4.88M
Commodore capital lp	-	-	-3.41M
State street	1.22M	0.00%	-1.58M
Tcg crossover management	-	-	-1.28M
Point72 asset management	196.47K	0.00%	-1.01M

New Positions

Holder	Shares	% Assets	Change	Value
Samlyn capital	3.02M	0.16%	3.02M	$10.87M
Susquehanna fundamental investments	108.66K	0.01%	108.66K	$391.19K
Lpl financial	22.10K	0.00%	22.10K	$102.10K
China universal asset management	14.97K	0.01%	14.97K	$53.88K
Deerfield management company, l.p. (series c)	12.53K	0.00%	12.53K	$20.05K

Sold Out

Holder	Change
Gradient investments	-25.00
Capital performance advisors llp	-54.00
Cape investment advisory	-100.00
Lindbrook capital	-100.00
Clear street markets	-143.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2025	6	-95.20%	21,025,800	-67.35%	30	0.35%	4	-93.85%	1	-96.97%
Dec 31, 2024	122	-5.43%	64,367,933	0.29%	92	1.09%	63	-7.35%	33	3.13%
Sep 30, 2024	126	5.88%	64,029,825	5.20%	91	1.18%	67	1.52%	33	-2.94%
Jun 30, 2024	119	7.21%	60,865,031	4.84%	88	1.23%	66	-1.49%	34	25.93%
Mar 31, 2024	111	16.84%	58,053,690	23.80%	84	1.01%	67	21.82%	27	8.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Wasatch Ultra Growth	4.56M	6.42%	1.17M
Vanguard US Total Market Shares ETF	2.14M	3.01%	-
Vanguard Total Stock Mkt Idx Inv	2.07M	2.92%	-
Biotech Growth Ord	1.75M	2.47%	-
SPDR® S&P Biotech ETF	1.57M	2.22%	22.34K
iShares Russell 2000 ETF	1.56M	2.20%	765.00
Vanguard Institutional Extnd Mkt Idx Tr	840.16K	1.18%	-
Wasatch Micro Cap	758.27K	1.07%	-483.88K
Fidelity Small Cap Index	599.35K	0.84%	-4.67K
iShares Russell 2000 Value ETF	562.16K	0.79%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Feb 18, 2025	Boyle Scott N	Chief Business Officer	Sell	$2.11K
Feb 14, 2025	Boyle Scott N	Chief Business Officer	Sell	$1.54K
Feb 08, 2023	Koppikar Utpal	-	Buy	$31.74K
Apr 12, 2022	Hirsch Andrew	President & CEO	Buy	$84.00K
Jan 04, 2022	Crystal Adam	Chief Medical Officer	Sell	$440.55K

Insider Transactions Trends

Date	Buy	Sell
2025 Q2	-	-
2025 Q1	-	2
2024 Q4	-	-
2024 Q3	-	-
2024 Q2	-	-

CCCC Ownership FAQ

Who Owns C4 Therapeutics?

C4 Therapeutics shareholders are primarily institutional investors at 30.31%, followed by 9.79% insiders and 59.90% retail investors. The average institutional ownership in C4 Therapeutics's industry, Biotech Stocks , is 63.95%, which C4 Therapeutics falls below.

Who owns the most shares of C4 Therapeutics?

C4 Therapeutics’s largest shareholders are Lynx1 capital management lp (7.1M shares, 10.23%), Soleus capital management (6.98M shares, 10.06%), and Orbimed advisors (6.83M shares, 9.85%). Together, they hold 30.14% of C4 Therapeutics’s total shares outstanding.

Does Blackrock own C4 Therapeutics?

Yes, BlackRock owns 6.61% of C4 Therapeutics, totaling 4.55M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 21.03M$. In the last quarter, BlackRock increased its holdings by 3.65M shares, a 402.93% change.

Who is C4 Therapeutics’s biggest shareholder by percentage of total assets invested?

Lynx1 capital management lp is C4 Therapeutics’s biggest shareholder by percentage of total assets invested, with 4.07% of its assets in 7.1M C4 Therapeutics shares, valued at 11.36M$.

Who is the top mutual fund holder of C4 Therapeutics shares?

Wasatch Ultra Growth is the top mutual fund holder of C4 Therapeutics shares, with 6.42% of its total shares outstanding invested in 4.56M C4 Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools